Wechselwirkungen von Venlafaxin

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Amfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (Fachinformation zu Amfetamin und Dexamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (Fachinformation zu Amiodaron, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (Fachinformation zu Azithromycin, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Belladonna und Opium, Arzneimittelwechselwirkungen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Buprenorphin, Arzneimittelwechselwirkungen)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Buprenorphin und Naloxon, Arzneimittelwechselwirkungen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Butalbital, Acetylsalicylsäure, Koffein und Codein, Arzneimittelwechselwirkungen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Butalbital, Paracetamol, Koffein und Codein, Arzneimittelwechselwirkungen)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Butorphanol, Vorsichtsmaßnahmen)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (Fachinformation zu Carbamazepin, Gegenanzeigen)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (Fachinformation zu Ciprofloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Codein, Arzneimittelwechselwirkungen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (Fachinformation zu Dexamfetamin, Arzneimittelwechselwirkungen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (Fachinformation zu Dofetilid, Warnhinweise)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (Fachinformation zu Dronedaron, Gegenanzeigen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (Fachinformation zu Edoxaban, Arzneimittelwechselwirkungen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (Fachinformation zu Emtricitabin, Rilpivirin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Fentanyl, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (Fachinformation zu Fluconazol, Gegenanzeigen)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (Fachinformation zu Flumazenil, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (Fachinformation zu Foscarnet, Arzneimittelwechselwirkungen)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (Fachinformation zu Fosfomycin, Arzneimittelwechselwirkungen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon, Arzneimittelwechselwirkungen)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Chlorphenamin, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Homatropin, Arzneimittelwechselwirkungen)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Hydrocodon und Ibuprofen, Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Hydrocodon und Paracetamol, Vorsichtsmaßnahmen)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydromorphon, Arzneimittelwechselwirkungen)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (Fachinformation zu Hydroxychloroquin, Warnhinweise und Vorsichtsmaßnahmen)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (Fachinformation zu Iloperidon, Arzneimittelwechselwirkungen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (Fachinformation zu Venlafaxin, Gegenanzeigen)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (Fachinformation zu Ivabradin, Warnhinweise und Vorsichtsmaßnahmen)

Die Kombination von Johanniskraut mit Antidepressiva und anderen serotonergen Arzneimitteln erhöht das Risiko eines Serotoninsyndroms. (NCCIH, St. John's Wort)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (Fachinformation zu Levofloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Levorphanol, Vorsichtsmaßnahmen)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (Fachinformation zu Venlafaxin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Lisdexamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (Fachinformation zu Lopinavir und Ritonavir, Warnhinweise und Vorsichtsmaßnahmen)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (Fachinformation zu Lorazepam, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (Fachinformation zu Metaxalon, Arzneimittelwechselwirkungen)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Methadon, Warnhinweise und Vorsichtsmaßnahmen)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (Fachinformation zu Venlafaxin, Gegenanzeigen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Morphin, Arzneimittelwechselwirkungen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oliceridin, Arzneimittelwechselwirkungen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (Fachinformation zu Oxaliplatin, Arzneimittelwechselwirkungen)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (Fachinformation zu Oxycodon, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oxymorphon, Arzneimittelwechselwirkungen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Paracetamol und Codein, Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Fachinformation zu Pazopanib, Arzneimittelwechselwirkungen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Pentazocin und Naloxon, Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Drugs that Prolong the QT Interval : Avoid concomitant use. (Fachinformation zu Phenobarbital, Arzneimittelwechselwirkungen)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (Fachinformation zu Pimozid, Gegenanzeigen)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (Fachinformation zu Pitolisant, Warnhinweise und Vorsichtsmaßnahmen)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (Fachinformation zu Promethazin, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Promethazin und Codein, Arzneimittelwechselwirkungen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (Fachinformation zu Propafenon, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (Fachinformation zu Venlafaxin, Gegenanzeigen)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Remifentanil, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (Fachinformation zu Venlafaxin, Gegenanzeigen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (Fachinformation zu Tetrabenazin, Arzneimittelwechselwirkungen)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (Fachinformation zu Thioridazin, Gegenanzeigen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (Fachinformation zu Vepdegestrant, Warnhinweise und Vorsichtsmaßnahmen)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (Fachinformation zu Venlafaxin, Boxed Warning (umrahmter Warnhinweis))

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (Fachinformation zu Ziprasidon, Gegenanzeigen)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (Fachinformation zu Adrenalin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (Fachinformation zu Arformoterol, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (Fachinformation zu Articain und Adrenalin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Fachinformation zu Bismutsubcitrat, Metronidazol und Tetracyclin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (Fachinformation zu Brimonidin, Arzneimittelwechselwirkungen)

Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (Fachinformation zu Brimonidin und Timolol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Budesonid und Formoterol, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (Fachinformation zu Bupivacain, Warnhinweise und Vorsichtsmaßnahmen)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (Fachinformation zu Bupivacain und Adrenalin, Warnhinweise und Vorsichtsmaßnahmen)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (Fachinformation zu Carbidopa, Levodopa und Entacapon, Arzneimittelwechselwirkungen)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (Fachinformation zu Carisoprodol, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (Fachinformation zu Chloroprocain, Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (Fachinformation zu Clonazepam, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Fachinformation zu Clopidogrel, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (Fachinformation zu Daridorexant, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (Fachinformation zu Desfluran, Warnhinweise und Vorsichtsmaßnahmen)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (Fachinformation zu Desmopressin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Diazepam Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Fachinformation zu Dicycloverin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (Fachinformation zu Dikaliumclorazepat, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (Fachinformation zu Dronabinol, Warnhinweise und Vorsichtsmaßnahmen)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (Fachinformation zu Droperidol, Warnhinweise)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (Fachinformation zu Eribulin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Fachinformation zu Eszopiclon, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (Fachinformation zu Formoterol, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (Fachinformation zu Fosphenytoin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Fachinformation zu Gefitinib, Arzneimittelwechselwirkungen)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (Fachinformation zu Glycopyrroniumbromid, Arzneimittelwechselwirkungen)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Fachinformation zu Goserelin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Haloperidol: Increase in Haloperidol AUC and C max . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (Fachinformation zu Ipratropiumbromid und Salbutamol, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (Fachinformation zu Isofluran, Warnhinweise und Vorsichtsmaßnahmen)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (Fachinformation zu Isoprenalin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (Fachinformation zu Kokain, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

TYKERB may prolong the QT interval in some patients. (Fachinformation zu Lapatinib, Warnhinweise und Vorsichtsmaßnahmen)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (Fachinformation zu Lemborexant, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Fachinformation zu Leuprorelin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (Fachinformation zu Levosalbutamol, Arzneimittelwechselwirkungen)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (Fachinformation zu Lidocain, Arzneimittelwechselwirkungen)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (Fachinformation zu Lidocain und Adrenalin, Warnhinweise und Vorsichtsmaßnahmen)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (Fachinformation zu Lumateperon, Warnhinweise und Vorsichtsmaßnahmen)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (Fachinformation zu Lurasidon, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (Fachinformation zu Mefloquin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (Fachinformation zu Mepivacain, Warnhinweise)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (Fachinformation zu Methylscopolamin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (Fachinformation zu Metronidazol, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (Fachinformation zu Moxifloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (Fachinformation zu Natriumoxybat, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (Fachinformation zu Paliperidon, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (Fachinformation zu Pasireotid, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (Fachinformation zu Phenylephrin, Arzneimittelwechselwirkungen)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (Fachinformation zu Phenytoin, Arzneimittelwechselwirkungen)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (Fachinformation zu Physostigmin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (Fachinformation zu Ponesimod, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (Fachinformation zu Prilocain und Adrenalin, Arzneimittelwechselwirkungen)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (Fachinformation zu Primaquin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (Fachinformation zu Quetiapin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (Fachinformation zu Rilpivirin, Warnhinweise und Vorsichtsmaßnahmen)

Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (Fachinformation zu Rocuronium, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salbutamol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (Fachinformation zu Scopolamin, Warnhinweise und Vorsichtsmaßnahmen)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (Fachinformation zu Sevofluran, Warnhinweise)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Fachinformation zu Sorafenib, Warnhinweise und Vorsichtsmaßnahmen)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (Fachinformation zu Sotalol, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (Fachinformation zu Sulfamethoxazol und Trimethoprim (Cotrimoxazol), Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Fachinformation zu Sunitinib, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (Fachinformation zu Temazepam, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Fachinformation zu Terbutalin, Vorsichtsmaßnahmen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (Fachinformation zu Toremifen, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Fachinformation zu Triptorelin, Warnhinweise und Vorsichtsmaßnahmen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Umeclidiniumbromid und Vilanterol, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (Fachinformation zu Vasopressin, Arzneimittelwechselwirkungen)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Patients receiving warfarin therapy should be carefully monitored when Venlafaxine Extended-Release Tablets are initiated or discontinued [see Warnings and Precautions ( 5.13 )] . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. (Fachinformation zu Zaleplon, Arzneimittelwechselwirkungen)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (Fachinformation zu Zolpidem, Warnhinweise und Vorsichtsmaßnahmen)

Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (Fachinformation zu Benzatropin, Warnhinweise)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (Fachinformation zu Brexpiprazol, Warnhinweise und Vorsichtsmaßnahmen)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (Fachinformation zu Carbidopa, Arzneimittelwechselwirkungen)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (Fachinformation zu Cariprazin, Warnhinweise und Vorsichtsmaßnahmen)

Postmarketing Spontaneous Drug Interaction Reports There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (Fachinformation zu Hydroxyzin, Vorsichtsmaßnahmen)

This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (Fachinformation zu Lovastatin, Warnhinweise)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (Fachinformation zu Perphenazin, Arzneimittelwechselwirkungen)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (Fachinformation zu Tiagabin, Warnhinweise)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (Fachinformation zu Trihexyphenidyl, Arzneimittelwechselwirkungen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (Fachinformation zu Valproat-Seminatrium (Divalproex), Arzneimittelwechselwirkungen)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (Fachinformation zu Valproinsäure, Arzneimittelwechselwirkungen)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when coadministered with ABILIFY MAINTENA. (Fachinformation zu Aripiprazol, Arzneimittelwechselwirkungen)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (Fachinformation zu Entacapon, Vorsichtsmaßnahmen)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (Fachinformation zu Ropinirol, Arzneimittelwechselwirkungen)